Heiner K Berthold

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3093026/heiner-k-berthold-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 5,234 123 32 h-index g-index citations papers 5,849 5.1 131 5.35 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
123	Vitamin D and Vascular Disease. <i>Current Vascular Pharmacology</i> , 2021 , 19, 250-268	3.3	8
122	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021 , 73, 730-76	5 2 22.5	27
121	Reply to Meshkini et al. European Journal of Clinical Nutrition, 2021 , 75, 990-991	5.2	O
120	The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Clinical Nutrition</i> , 2021 , 75, 980-987	5.2	10
119	A 3Iyear post-intervention follow-up on mortality in advanced heart failure (EVITA vitamin D supplementation trial). <i>ESC Heart Failure</i> , 2020 , 7, 3754	3.7	3
118	The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019 , 317, E411-E420	6	18
117	Daily Supplementation with 4000 IU Vitamin D3 for Three Years Does Not Modify Cardiovascular Risk Markers in Patients with Advanced Heart Failure: The Effect of Vitamin D on Mortality in Heart Failure Trial. <i>Annals of Nutrition and Metabolism</i> , 2019 , 74, 62-68	4.5	4
116	Vitamin D supplementation does not prevent the testosterone decline in males with advanced heart failure: the EVITA trial. <i>European Journal of Nutrition</i> , 2019 , 58, 673-680	5.2	7
115	Vitamin D supplementation and bone turnover in advanced heart failure: the EVITA trial. Osteoporosis International, 2018 , 29, 579-586	5.3	8
114	Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial. <i>International Journal of Endocrinology</i> , 2018 , 2018, 5015417	2.7	16
113	Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. <i>European Heart Journal</i> , 2017 , 38, 2279-2286	9.5	101
112	Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. <i>Current Pharmaceutical Design</i> , 2017 , 23, 4573-4582	3.3	4
111	Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 655-63	3.8	9
110	IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. <i>Journal of Lipid Research</i> , 2015 , 56, 1034-42	6.3	77
109	Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2015 , 18, 28-34	1.7	36
108	Treatment of Cardiovascular Risk Factors in Women. Current Medicinal Chemistry, 2015, 22, 3580-96	4.3	6
107	Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E45-52	5.6	131

(2011-2014)

106	Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial. <i>PLoS ONE</i> , 2014 , 9, e91565	3.7	10
105	PCSK9 antibodies for the treatment of hypercholesterolemia. <i>Nutrients</i> , 2014 , 6, 5517-33	6.7	17
104	Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5025-38	3.3	3
103	Familial hypercholesterolemia: etiology, diagnosis and new treatment options. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6220-9	3.3	4
102	Hyperlipoproteinemia(a): clinical significance and treatment options. <i>Atherosclerosis Supplements</i> , 2013 , 14, 1-5	1.7	15
101	Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. <i>Scandinavian Cardiovascular Journal</i> , 2013 , 47, 20-7	2	9
100	Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity?. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 108-12	4.6	4
99	Lipidapherese. <i>CardioVasc</i> , 2013 , 13, 48-52	О	2
98	Selenium and hypertension: do we need to reconsider selenium supplementation in cancer patients?. <i>Journal of Hypertension</i> , 2013 , 31, 1050-2	1.9	1
97	Mipomersen: a lipid-lowering agent with a novel mechanism of action. Clinical Lipidology, 2013, 8, 279-2	.82	1
96	Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. <i>PLoS ONE</i> , 2013 , 8, e60095	3.7	48
95	Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. <i>PLoS ONE</i> , 2013 , 8, e72858	3.7	81
94	The role of niacin in lipid-lowering treatment: are we aiming too high?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3094-106	3.3	12
93	Novel approaches to the pharmacotherapy of obesity. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4938-52	23.3	7
92	The whey fermentation product malleable protein matrix decreases TAG concentrations in patients with the metabolic syndrome: a randomised placebo-controlled trial. <i>British Journal of Nutrition</i> , 2012 , 107, 1694-706	3.6	20
91	Influence of serum selenium concentrations on hypertension: the Lipid Analytic Cologne cross-sectional study. <i>Journal of Hypertension</i> , 2012 , 30, 1328-35	1.9	31
90	Heat shock protein-60 and risk for cardiovascular disease. Current Pharmaceutical Design, 2011, 17, 366	2₃8 ₃	28
89	The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: a randomized placebo-controlled trial. <i>Journal of Dairy Science</i> , 2011 , 94, 589-601	4	11

88	Antisense oligonucleotides for the treatment of dyslipidemia. <i>Current Pharmaceutical Design</i> , 2011 , 17, 950-60	3.3	15
87	Role of physician gender in the quality of care of cardiometabolic diseases. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3690-8	3.3	2
86	Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2011 , 94, 479-85	7	229
85	Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 858-61		2
84	Lipid-lowering drug therapy in elderly patients. Current Pharmaceutical Design, 2011, 17, 877-93	3.3	18
83	Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. <i>PLoS ONE</i> , 2011 , 6, e24719	3.7	26
82	Lipoprotein(a): current perspectives. Current Vascular Pharmacology, 2011, 9, 682-92	3.3	26
81	Disease management programs in type 2 diabetes: quality of care. <i>American Journal of Managed Care</i> , 2011 , 17, 393-403	2.1	13
80	Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2010 , 27, 303-8	3.5	2
79	Lifibrol as a model compound for a novel lipid-lowering mechanism of action. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010 , 15, 364-72	2.6	
78	Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. <i>European Heart Journal</i> , 2010 , 31, 1633-9	9.5	57
77	Influence of ghrelin gene polymorphisms on hypertension and atherosclerotic disease. <i>Hypertension Research</i> , 2010 , 33, 155-60	4.7	17
76	Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia. <i>Lipids</i> , 2010 , 45, 491-500	1.6	4
75	Bolus ingestion of white and green tea increases the concentration of several flavan-3-ols in plasma, but does not affect markers of oxidative stress in healthy non-smokers. <i>Molecular Nutrition and Food Research</i> , 2010 , 54, 1636-45	5.9	19
74	Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. <i>American Journal of Clinical Nutrition</i> , 2009 , 89, 1321-7	7	404
73	Vitamin D and cardiovascular disease. Current Vascular Pharmacology, 2009 , 7, 414-22	3.3	86
72	Use of the lactose-[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test. <i>Journal of Gastroenterology</i> , 2009 , 44, 944-51	6.9	13
71	Patterns and predictors of statin prescription in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2009 , 8, 25	8.7	28

(2006-2009)

70	A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-reduced diets in patients attending a telemedically guided weight loss program. <i>Cardiovascular Diabetology</i> , 2009 , 8, 36	8.7	52
69	The stable isotope ketoisocaproic acid breath test as a measure of hepatic decarboxylation capacity: a quantitative analysis in normal subjects after oral and intravenous administration. <i>Liver International</i> , 2009 , 29, 1356-64	7.9	12
68	The Leu72Met polymorphism of the ghrelin gene is associated with a decreased risk for type 2 diabetes. <i>Clinica Chimica Acta</i> , 2009 , 399, 112-6	6.2	19
67	Supplementation with a multivitamin containing 800 microg of folic acid shortens the time to reach the preventive red blood cell folate concentration in healthy women. <i>International Journal for Vitamin and Nutrition Research</i> , 2009 , 79, 61-70	1.7	38
66	Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). <i>Atherosclerosis Supplements</i> , 2009 , 10, 85-8	1.7	15
65	Effect of a cellulose-containing weight-loss supplement on gastric emptying and sensory functions. <i>Obesity</i> , 2008 , 16, 2272-80	8	13
64	Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure. <i>European Journal of Clinical Nutrition</i> , 2008 , 62, 1388-94	5.2	16
63	Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. <i>Clinical Endocrinology</i> , 2008 , 68, 536-41	3.4	37
62	Physician gender is associated with the quality of type 2 diabetes care. <i>Journal of Internal Medicine</i> , 2008 , 264, 340-50	10.8	120
61	High-dose oral supplementation of antioxidants and glutamine improves the antioxidant status in patients with Crohnß disease: A pilot study. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2008 , 3, e246-e253		10
60	Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. <i>Atherosclerosis</i> , 2008 , 198, 198-207	3.1	46
59	Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. <i>Diabetes Care</i> , 2008 , 31, 1389-91	14.6	125
58	SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2008 , 116, 262-	7 ^{2.3}	15
57	Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. <i>Clinical Transplantation</i> , 2007 , 21, 536-43	3.8	60
56	The K121Q polymorphism of the plasma cell glycoprotein-1 gene is not associated with diabetes mellitus type 2 in German Caucasians. <i>Hormone and Metabolic Research</i> , 2006 , 38, 524-9	3.1	13
55	Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 2262-9	27.4	129
54	Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. <i>Drug Safety</i> , 2006 , 29, 703-12	5.1	66
53	Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2006 , 83, 754-	.97	715

52	Association of the promoter polymorphism -232C/G of the phosphoenolpyruvate carboxykinase gene (PCK1) with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2006 , 23, 419-25	3.5	8
51	The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. <i>Atherosclerosis</i> , 2005 , 183, 336-41	3.1	26
50	Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. <i>Journal of Hypertension</i> , 2005 , 23, 301-8	1.9	22
49	Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. <i>Transplantation</i> , 2005 , 79, 981-3	1.8	36
48	The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population. <i>Journal of Internal Medicine</i> , 2005 , 257, 272-80	10.8	12
47	Resistin gene 3Runtranslated region +62G>A polymorphism is associated with hypertension but not diabetes mellitus type 2 in a German population. <i>Journal of Internal Medicine</i> , 2005 , 258, 518-26	10.8	20
46	The low pressure stent observational trial on the procedural and mid-term outcome of a trapezoid-shaped coronary stent (LOPSTER). <i>Journal of Interventional Cardiology</i> , 2005 , 18, 323-9	1.8	
45	Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 371-80	5.3	16
44	Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). <i>Journal of Invasive Cardiology</i> , 2005 , 17, 199-202	0.7	5
43	Clinical and angiographic procedural and mid-term outcome with new versus reused balloon catheters in percutaneous coronary interventions. <i>Indian Heart Journal</i> , 2005 , 57, 114-20	1.6	1
42	Lymphocyte proliferation and apoptosis in HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit-vegetable-concentrate rich in polyphenols and antioxidant vitamins. <i>European Journal of Clinical Nutrition</i> , 2004 , 58, 317-25	5.2	17
41	Short-term effects of high soy supplementation on sex hormones, bone markers, and lipid parameters in young female adults. <i>European Journal of Nutrition</i> , 2004 , 43, 100-8	5.2	26
40	Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women. <i>Osteoporosis International</i> , 2004 , 15, 459-67	5.3	29
39	Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. <i>American Heart Journal</i> , 2004 , 147, 1117-24	4.9	27
38	Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia. <i>British Journal of Nutrition</i> , 2004 , 91, 959-69	3.6	41
37	Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults. <i>Calcified Tissue International</i> , 2003 , 73, 356-60	3.9	16
36	Comparison of a silicon carbide coated stent versus a noncoated stent in humans: the Tenax-versus Nir-Stent Study (TENISS). <i>Journal of Interventional Cardiology</i> , 2003 , 16, 325-33	1.8	27
35	Lipoprotein(a) concentration increases during treatment with carbamazepine. <i>Epilepsia</i> , 2003 , 44, 457-	6 6.4	52

34	Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study. <i>European Journal of Clinical Nutrition</i> , 2003 , 57, 1262-7	5.2	24
33	Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 105-12	15.1	388
32	Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Studyß long-term outcome. <i>American Heart Journal</i> , 2003 , 145, e17	4.9	30
31	Low serum levels of intact osteocalcin in patients with congestive heart failure. <i>Journal of Bone and Mineral Metabolism</i> , 2003 , 21, 247-52	2.9	19
30	Oral contraceptives moderately effect bone resorption markers and serum-soluble interleukin-6 receptor concentrations. <i>Calcified Tissue International</i> , 2002 , 70, 11-21	3.9	5
29	Restenosis rates with flexible GFX stents (REFLEX): clinical and angiographic results. <i>Journal of Interventional Cardiology</i> , 2002 , 15, 269-75	1.8	1
28	Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. <i>Gut</i> , 2002 , 51, 860-3	19.2	61
27	Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. <i>Chest</i> , 2002 , 122, 829-39	5.3	255
26	5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. <i>American Journal of Clinical Nutrition</i> , 2002 , 75, 275-82	7	80
25	Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H704-16	5.2	22
24	Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. <i>American Heart Journal</i> , 2002 , 143, 356-65	4.9	176
23	Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , 2001 , 363, 215-21	3.4	28
22	Effects of authentic and VLDL hydrolysis-derived fatty acids on vascular smooth muscle cell growth. British Journal of Pharmacology, 2001 , 132, 1725-34	8.6	9
21	Plasma antioxidant capacity of HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit-vegetable-concentrate containing antioxidant polyphenols. <i>European Journal of Clinical Nutrition</i> , 2001 , 55, 786-92	5.2	12
20	Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001 , 109, 203-9	2.3	12
19	Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy. <i>Metabolism: Clinical and Experimental</i> , 2001 , 50, 1275-81	12.7	14
18	Short-term stimulation of vascular smooth muscle cells with platelet-derived growth factor (PDGF)-BB and angiotensin II induces. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2000 , 60, 723-31	2	1
17	Influence of protease inhibitor therapy on lipoprotein metabolism. <i>Journal of Internal Medicine</i> , 1999 , 246, 567-75	10.8	7 ²

16	Improvement of sarcoidosis under therapy with interferon-alpha 2b for chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 1999 , 30, 347	13.4	11
15	Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 279, 1900-2	27.4	135
14	Garlic preparations for prevention of atherosclerosis. Current Opinion in Lipidology, 1998, 9, 565-9	4.4	26
13	Failure of the nonselective beta-blocker propranolol to affect lipoprotein lipase gene expression in the rat. <i>Lipids</i> , 1997 , 32, 943-7	1.6	1
12	Isotopic evidence for the differential regulation of arginine and proline synthesis in man. <i>Metabolism: Clinical and Experimental</i> , 1995 , 44, 466-73	12.7	28
11	Evidence for incorporation of intact dietary pyrimidine (but not purine) nucleosides into hepatic RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 10123-7	11.5	28
10	Leucine oxidation changes rapidly after dietary protein intake is altered in adult women but lysine flux is unchanged as is lysine incorporation into VLDL-apolipoprotein B-100. <i>Journal of Nutrition</i> , 1994 , 124, 41-51	4.1	32
9	The use of uniformly labelled substrates and mass isotopomer analysis to study intermediary metabolism. <i>Proceedings of the Nutrition Society</i> , 1994 , 53, 345-54	2.9	10
	Verwendung von [13C]Laktose-Ureid in einem neuen Atemtest zur Bestimmung von intestinaler		
8	bakterieller Besiedlung und intestinaler Passagezeit. <i>Isotopes in Environmental and Health Studies</i> , 1992 , 28, 32-32		
7	bakterieller Besiedlung und intestinaler Passagezeit. Isotopes in Environmental and Health Studies,	11.5	57
	bakterieller Besiedlung und intestinaler Passagezeit. <i>Isotopes in Environmental and Health Studies</i> , 1992 , 28, 32-32 Uniformly 13C-labeled algal protein used to determine amino acid essentiality in vivo. <i>Proceedings</i>	11.5	<i>57</i>
7	bakterieller Besiedlung und intestinaler Passagezeit. <i>Isotopes in Environmental and Health Studies</i> , 1992 , 28, 32-32 Uniformly 13C-labeled algal protein used to determine amino acid essentiality in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 8091-5 Identification of cardiotonic sodium channel activators by potassium depolarization in isolated	11.5 3.4	
7	bakterieller Besiedlung und intestinaler Passagezeit. <i>Isotopes in Environmental and Health Studies</i> , 1992 , 28, 32-32 Uniformly 13C-labeled algal protein used to determine amino acid essentiality in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 8091-5 Identification of cardiotonic sodium channel activators by potassium depolarization in isolated guinea-pig atria. <i>Journal of Pharmacological Methods</i> , 1990 , 24, 121-35 Cardiovascular effects of endothelin 1 in pithed spontaneously hypertensive rats: evaluation of its		7
7 6 5	bakterieller Besiedlung und intestinaler Passagezeit. <i>Isotopes in Environmental and Health Studies</i> , 1992, 28, 32-32 Uniformly 13C-labeled algal protein used to determine amino acid essentiality in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 8091-5 Identification of cardiotonic sodium channel activators by potassium depolarization in isolated guinea-pig atria. <i>Journal of Pharmacological Methods</i> , 1990, 24, 121-35 Cardiovascular effects of endothelin 1 in pithed spontaneously hypertensive rats: evaluation of its mechanism(s) of action. <i>Naunyn-Schmiedeberga Archives of Pharmacology</i> , 1989, 340, 424-30 Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3	3.4	7
7 6 5 4	bakterieller Besiedlung und intestinaler Passagezeit. <i>Isotopes in Environmental and Health Studies</i> , 1992, 28, 32-32 Uniformly 13C-labeled algal protein used to determine amino acid essentiality in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 8091-5 Identification of cardiotonic sodium channel activators by potassium depolarization in isolated guinea-pig atria. <i>Journal of Pharmacological Methods</i> , 1990, 24, 121-35 Cardiovascular effects of endothelin 1 in pithed spontaneously hypertensive rats: evaluation of its mechanism(s) of action. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , 1989, 340, 424-30 Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3 receptor antagonist ICS 205-930. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , 1989, 339, 259-62 Enigmatic action of ciclosporine A on the naloxone-precipitated morphine withdrawal syndrome in	3.4	7 6 11